You just read:

Shire Reports Positive Phase 2 Study Met Primary End Point for Investigative Use of Vyvanse® (lisdexamfetamine dimesylate) Capsules, (CII) in Adults with Binge Eating Disorder

News provided by

Shire plc

Apr 26, 2012, 06:00 ET